Skip to main content
OpenTrials
Completed

NCT Number: NCT04980807

Observational Study of Neuromuscular Function in CMT Type 1&2 and Healthy Controls

The primary aim of this study is to discover whether patients with CMT type 1 and 2 have neuromuscular junction transmission deficits.

The secondary aim is to collect information of different clinical and electrophysiological test procedures to perform possible future clinical trials in CMT patients.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The study is a prospective observational pilot study involving two investigational sites:

  • Department of Neurology, Arhus University Hospital
  • Department of Neurology, Ohio State University

A total of 20 patients with Charcot-Marie-Tooth (CMT) disease and 10 healthy age-matched controls will be included with each site including 10 CMT patients and 5 Healthy Controls. CMT patients will undergo electrophysiological (repetitive nerve stimulation and single fiber EMG analyses) and functional (different tests of muscle strength, fatigability, dexterity, and balance) testing on 4 separate occasions. Healthy controls will undergo electrophysiological testing at baseline only.

To assess whether patients with CMT have deficits in NMJ transmission, results from repetitive nerve stimulation and single fiber EMG analyses in CMT patients will be compared to those obtained in healthy controls at baseline. To inform future clinical trials, results relability and tolerability estimates obtained from sequential electrophysiological and functional tests will be calculated

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for CMT Patients

  • Age ≥ 18 years
  • Diagnosis of CMT confirmed by:
  • Clinical presentation and electro diagnostics or genetics
  • Physical Features (all must apply): 1) Ambulation for at least 10 meters, without a brace 2) Left and right ankle plantar flexion Medical Research Council (MRC) grade 2 to 5, inclusive 3) Left and right ankle dorsiflexion MRC manual muscle testing (MMT) grade 2 to 4+, inclusive.
  • Ability to adhere to the study visit schedule/procedures, and to understand and comply with protocol requirements
  • Stable concomitant medications for 2 months prior to enrolment
  • Signed written informed consent

Exclusion criteria

for CMT Patients

  • Severe deformity or ankle contracture that would sufficiently limit passive range of motion to affect assessment of dorsiflexion strength
  • Ulceration that would interfere with functional ability
  • Recent major surgery
  • Significant change in physical activity or exercise (e.g., significant increase or decrease in intensity or frequency) within 8 weeks before Study Day 1 or inability to maintain the baseline level of physical activity throughout the study
  • Any disability or condition that would prevent completion of the study tasks
  • Moderate to severe Neuropathic or inflammatory/musculoskeletal pain that would interfere with performance of the tests
  • A diagnosis of a primary NMJ disorder such as myasthenia gravis, Lambert Eaton Myasthenic Syndrome or congenital myasthenic disorder

Inclusion criteria

for Healthy Volunteers

  • Healthy male or female volunteers
  • Age ≥18 years
  • Able to give written informed consent

Exclusion criteria

for Healthy Volunteers

  • Pregnant
  • Requiring prescription medicines likely to interfere with electromyography (EMG) recordings
  • Presence of current or previous medical condition which might interfere with participation in the study

Treatment and study plan

Primary outcomes

  1. Repetitive Nerve Stimulation - difference between CMT patients and healthy controls

    Time frame: Baseline

    Percentage decrement of CMAP for the trapezius

  2. Repetitive Nerve Stimulation - difference between CMT patients and healthy controls

    Time frame: Baseline

    Percentage decrement of CMAP for abductor pollicis brevis

  3. Single Fiber Electro Myography (sfEMG) - difference between CMT patients and healthy controls

    Time frame: Baseline

    Percentage blocking

  4. Single Fiber Electro Myography (sfEMG) - difference between CMT patients and healthy controls

    Time frame: Baseline

    Jitter

Secondary outcomes

  1. Isometric Dynamometry - test reliability in patients with CMT

    Time frame: The test is performed at baseline and day 14, 28 and 42.

    This test will be used to evaluate maximum isometric strength

  2. Manual Muscle Testing - test reliability in patients with CMT

    Time frame: The test is performed at baseline and day 14, 28 and 42.

    This test is a physical examination of muscle strength. 15 muscle groups/motions will be tested. 13 of these are tested bilaterally. A total score between (0-280) is calculated

  3. 9 Hole Peg Test - test reliability in patients with CMT

    Time frame: The test is performed at baseline and day 14, 28 and 42.

    This is a test of finger dexterity

  4. 6-Spot Step Test - test reliability in patients with CMT

    Time frame: The test is performed at baseline and day 14, 28 and 42.

    This test is a quantitative measure of lower extremity function

  5. 10-Meter Walk/run Test - test reliability in patients with CMT

    Time frame: The test is performed at baseline and day 14, 28 and 42.

    This test measures how fast the participant can walk/run 10 meters.

  6. Timed Up and Go - test reliability in patients with CMT

    Time frame: The test is performed at baseline and day 14, 28 and 42.

    This test measures how fast the participant can stand from a chair, walk 3 meters, turn around, return, and sit in the chair at a comfortable and safe pace

  7. Berg Balance Scale - test reliability in patients with CMT

    Time frame: The test is performed at baseline and day 14, 28 and 42.

    The test measures balance during different functional tasks. A total score is calculated as the sum of the individual scores for each item, with maximum value 56, with a lower score meaning worse balance

  8. 6 Minute Walk Test - test reliability in patients with CMT

    Time frame: The test is performed at baseline and day 14, 28 and 42.

    This test measures how far a person can walk in six minutes

  9. Single Fiber Electro Myography (sfEMG) - test reliability in patients with CMT

    Time frame: The test is performed at baseline and day 14, 28 and 42.

    Percantage blocking

  10. Single Fiber Electro Myography (sfEMG) - test reliability in patients with CMT

    Time frame: The test is performed at baseline and day 14, 28 and 42.

    Jitter

  11. Repetitive Nerve Stimulation - test reliability in patients with CMT

    Time frame: The test is performed at baseline and day 14, 28 and 42.

    Percentage decrement of CMAP for Trapezius

  12. Repetitive Nerve Stimulation - test reliability in patients with CMT

    Time frame: The test is performed at baseline and day 14, 28 and 42.

    Percentage decrement of CMAP for abductor pollicis brevis

Other outcomes

  1. CMTES2 Score

    Time frame: This test is performed at baseline in individuals with CMT disease

    This test measures CMT disease severity. Total score is calculated as the sum of the 7 sub-scores with a maximum of score of 28

  2. Adverse Events

    Time frame: At baseline for healthy controls and from baseline until final visit at day 42 for CMT patients

    Number of adverse events by severity

  3. Tolerability of test procedures

    Time frame: Performed for each test at each visit (baseline, day 14, 28 and 42)

    The tolerability score assessed on a 0-9 rating scale (0=no discomfort to 9=worst possible discomfort)

  4. Association between NMJ function and clinical function in CMT patients

    Time frame: Baseline

    Correlation

Sponsors and collaborators

Lead sponsor

NMD Pharma A/S

Industry

Collaborators

  • Aarhus University Hospital
  • Ohio State University

Registry information

Official study title

An Open Observational Study of Clinical and Electrophysiological Outcomes in Male and Female Patients With CMT Type 1 & 2, and Aged-matched Healthy Controls

Acronym: ESTABLISH

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jul 28, 2021
Registry last updated
Mar 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.